{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:49:21Z","timestamp":1791485361501,"version":"4.3.4"},"reference-count":38,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. pediatr. gastroenterol. nutr."],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The aim of the study was to summarize short\u2010term effectiveness, safety, and cost of using infliximab biosimilar (IFX\u2010B) drugs, (Inflectra [Hospira] and Remsima [NAAP]) compared to originator infliximab (IFX\u2010O) (Remicade [MSD]) in biologic naive pediatric inflammatory bowel disease in the United Kingdom.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Prospective audit of patients starting anti\u2010tumour necrosis factor (TNF) therapy. Disease severity, response to treatment, and remission rate was measured by Pediatric Crohn's Disease Activity Index (PCDAI) and\/or Physician Global Assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Between March 2015 and February 2016, 278 patients (175 IFX\u2010O, 82 IFX\u2010B, and 21 Adalimumab) were started on anti\u2010TNF therapy. This was compared with collected data on 398 patients started on IFX\u2010O from 2011 to 2015. At initiation, median PCDAI was 36 (20,48) (n = 42) in the IFX\u2010O group and 28 (20,40) (n = 29) in the IFX\u2010B group, (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.08). Immunosuppression rates were similar: 150\/175 (86%) for IFX\u2010O and 65\/82 (79%) for IFX\u2010B (\n                      <jats:italic>P<\/jats:italic>\n                      &gt; 0.05). Post induction, median PCDAI score was 5 (0,11) (n = 19) and 0 (0,8) (n = 15) in the IFX\u2010O and IFX\u2010B groups, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.35). There was no difference in response to treatment using Physician Global Assessment 85% (n = 28) in IFX\u2010O group and 86% (n = 19) in IFX\u2010B group (\n                      <jats:italic>P<\/jats:italic>\n                      &gt; 0.05). Adverse events at initiation and post induction were not different between both groups (\n                      <jats:italic>P<\/jats:italic>\n                      &gt; 0.05). Using conservative calculations, \u00a3875,000 would have been saved for a 1\u2010year period with universal adoption of biosimilars in patients who were instead treated with IFX\u2010O.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>IFX\u2010B is likely as effective as IFX\u2010O in treating IBD in comparable pediatric populations. Sites should adopt infliximab biosimilar for new starts due to cost reduction with no difference in other parameters.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mpg.0000000000002011","type":"journal-article","created":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T16:18:12Z","timestamp":1524673092000},"page":"513-519","source":"Crossref","is-referenced-by-count":35,"title":["Use of Infliximab Biosimilar Versus Originator in a Pediatric United Kingdom Inflammatory Bowel Disease Induction Cohort"],"prefix":"10.1002","volume":"67","author":[{"given":"Neil","family":"Chanchlani","sequence":"first","affiliation":[{"name":"Homerton University Hospital NHS Foundation Trust London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajal","family":"Mortier","sequence":"additional","affiliation":[{"name":"UK IBD Audit Royal College of Physicians London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda J.","family":"Williams","sequence":"additional","affiliation":[{"name":"Usher Institute of Population Health Sciences &amp; Informatics University of Edinburgh Edinburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafeeq","family":"Muhammed","sequence":"additional","affiliation":[{"name":"Birmingham Children's Hospital, Birmingham Birmingham Children's Hospital Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus K.H.","family":"Auth","sequence":"additional","affiliation":[{"name":"Alder Hey Children's Hospital and University of Liverpool Liverpool"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Cosgrove","sequence":"additional","affiliation":[{"name":"Morriston Hospital Abertawe Bro Morgannwg University Health Board Wales"},{"name":"Children's Hospital for Wales Heath Park Cardiff"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Fagbemi","sequence":"additional","affiliation":[{"name":"Royal Manchester Children's Hospital Manchester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fell","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonny","family":"Chong","sequence":"additional","affiliation":[{"name":"Queen Mary's Hospital for Children (Epsom and St Helier University Hospitals) Sutton Carshalton"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Zamvar","sequence":"additional","affiliation":[{"name":"Clarendon Wing Leeds General Infirmary Leeds West Yorkshire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Hyer","sequence":"additional","affiliation":[{"name":"Northwick Park and St Mark's Hospital Harrow Middlesex"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Michael","family":"Bisset","sequence":"additional","affiliation":[{"name":"NHS Grampian Aberdeen Royal Infirmary Foresterhill Aberdeen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary\u2010Anne","family":"Morris","sequence":"additional","affiliation":[{"name":"Jenny Lind Children's Hospital Norfolk and Norwich University Hospital Norwich"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astor","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Children's Hospital John Radcliffe Hospital Headley Way Oxford"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally G.","family":"Mitton","sequence":"additional","affiliation":[{"name":"St George's Hospital, Tooting London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Bunn","sequence":"additional","affiliation":[{"name":"Great North Children's Hospital Royal Victoria Infirmary Newcastle upon Tyne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Mark","family":"Beattie","sequence":"additional","affiliation":[{"name":"Southampton Children's Hospital Tremona Road Southampton"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Willmott","sequence":"additional","affiliation":[{"name":"Leicester Royal Infirmary Infirmary Square Leicester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Royal Hospital for Sick Children Edinburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Russell","sequence":"additional","affiliation":[{"name":"Royal Hospital for Children Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.228"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21152"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21349"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000903"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21145"},{"key":"e_1_2_7_7_2","volume-title":"TA187 Inflxixmab (Review) and Adalimumab for the Treatment of Crohn's Disease","author":"National Institute for Health and Care Excellence.","year":"2010"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1936"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04603.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2013-305812"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001679"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e31828133d6"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12473"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.082909"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1536-4801.1991.tb10268.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.05.029"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000183350.46795.42"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.01.001"},{"key":"e_1_2_7_19_2","volume-title":"Biosimilar Medicines KTT15","author":"National Institute for Health and Care Excellence.","year":"2016"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2017-313404"},{"key":"e_1_2_7_21_2","volume-title":"Infliximab, Adalimumab and Golimumab for Treating Moderately to Severely Active Ulcerative Colitis After the Failure Of Conventional Therapy TA329","author":"National Institute for Health and Care Excellence.","year":"2015"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.07.019"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw198"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001572"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001643"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv220"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2016.1149883"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13990"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv096"},{"key":"e_1_2_7_30_2","volume-title":"Hospital Prescribing","author":"Health and Social Care Information Centre.","year":"2012"},{"key":"e_1_2_7_31_2","unstructured":"National Institute of Clinical Excellence.Infliximab and Adalimumab for the treatment of Crohn's disease. TA187. Available at:https:\/\/www.nice.org.uk\/guidance\/ta187\/chapter\/3\u2010the\u2010technologies. Accessed January 1 2018."},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0233-1"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv233"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izx047"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-017-4657-0"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-014-3392-z"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2017.1369561"},{"key":"e_1_2_7_39_2","first-page":"297","article-title":"Switching from Remicade(R) to Remsima(R) is well tolerated and feasible: a prospective, open\u2010label study","volume":"11","author":"Buer LC","year":"2017","journal-title":"J Crohns Colitis"}],"container-title":["Journal of Pediatric Gastroenterology and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1097\/MPG.0000000000002011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T06:19:49Z","timestamp":1750141189000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1097\/MPG.0000000000002011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1097\/MPG.0000000000002011"],"URL":"https:\/\/doi.org\/10.1097\/mpg.0000000000002011","archive":["Portico"],"relation":{},"ISSN":["0277-2116","1536-4801"],"issn-type":[{"value":"0277-2116","type":"print"},{"value":"1536-4801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}